DeCure for LIPE-related familial partial lipodystrophy
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for LIPE-related familial partial lipodystrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLIPE-related familial partial lipodystrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lipe-related familial partial lipodystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipase E, hormone sensitive type (LIPE) — LIPE is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8ZVQ · 3.4 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2025 case report describes a patient with familial partial lipodystrophy type 6 caused by a heterozygous LIPE gene mutation. The mutation was heterozygous, and the clinical presentation was milder as a result. The diagnosis was made through genetic testing. The authors state that clinicians should maintain a high index of suspicion for such rare cases and offer genetic testing when indicated.
A 2002 review notes that lipodystrophy syndromes are rare disorders of adipose tissue loss, which can be genetic, immune, or drug-associated. Metabolic complications such as insulin resistance, diabetes, hypertriglyceridemia, and fatty liver increase with the extent of fat loss. Causative mutations had recently been identified in one familial and one acquired form at that time.
A 2025 review of pharmacological therapies states there is no definitive cure for lipodystrophy syndromes. Management remains symptomatic. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment. Conventional therapies target specific complications. Novel interventions are under investigation, but the review offers no concrete survival or response rate data for any drug in LIPE-related lipodystrophy specifically.
No trial has tested a drug specifically for LIPE-related familial partial lipodystrophy. What is missing is any dedicated clinical trial, any patient stratification by genotype, and any funding for such a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Klinische Pädiatrie · 2002 · 7 citations
Lipodystrophien - Übersicht, Stand der Forschung, Klassifikation, neue Therapien -
AbstractThe lipodystrophy syndromes are rare disorders characterized by the loss of adipose tissue. The loss of fat tissue can have genetic, immune, or infectious/drug-associated causes. With the extent of fat loss metabolic complications, such as insulin resistance, diabetes mellitus, hypertriglyceridemia, and fatty liver increase in severity. Lipodystrophies can be divided into two subtypes: familial and acquired. Causative mutations have recently been identified in one form of familial lipodystrophy as well as in one form of acquired lipodystrophy. Several mouse models might help understanding the development of these syndrome. In this review article, the recently introduced classification of lipodystrophy syndromes is presented as well as new insights into pathogenesis and therapeutic strategies.
Expert Review of Endocrinology & Metabolism · 2025 · 2 citations · open access
Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions
AbstractINTRODUCTION: Lipodystrophy syndromes are a heterogeneous group of rare disorders characterized by partial or generalized loss of adipose tissue, which may be either inherited or acquired. Loss of adipose tissue in typical storage sites starting from birth or later in life, combined with abnormal fat accumulation in other organs, contributes to multiple metabolic complications. There is currently no definitive cure available for lipodystrophy syndromes, and clinical management remains symptomatic. AREAS COVERED: For this review, available databases were searched to identify publications and studies on current and emerging therapies to discuss the management of lipodystrophy syndromes. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment, while conventional therapies are used to target specific complications. Novel interventions are under investigation to address unmet clinical needs. EXPERT OPINION: There is currently no cure for lipodystrophy syndromes. Emerging therapies are being investigated to expand therapeutic options and improve long-term outcomes of this complex disorder.
Journal of the Association of Physicians of India · 2025 · 1 citations
Interesting Case of Familial Partial Lipodystrophy Syndrome (Type 6) with LIPE Gene Defect: A Case Report
AbstractWe report on an interesting case of familial partial lipodystrophy syndrome (type 6) due to a LIPE gene defect. Lipodystrophy syndromes are characterized by dysfunctional adipose tissue. While there are several types of lipodystrophies, this report is of a case of familial partial lipodystrophy with a LIPE gene mutation, which is very rare. Because the LIPE gene defect was of heterozygous nature, it presented in a milder clinical form. Thanks to genetic testing, we were able to clinch the diagnosis in this case. This case teaches us that we should have a high index of suspicion to pick up such rare cases and to offer genetic testing whenever indicated.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
